Sustained Elevation of MG53 in the Bloodstream Increases Tissue Regenerative Capacity Without Compromising Metabolic Function

Overview

Journal Nat Commun

Specialty Biology

Date 2019 Oct 13

PMID 31604915

Citations 40

Authors

Zehua Bian

Qiang Wang

Xinyu Zhou

Tao Tan

Ki Ho Park

H Fritz Kramer

Alan McDougal

Nicholas J Laping

Sanjay Kumar

T M Ayodele Adesanya

Matthew Sermersheim

Frank Yi

Xinxin Wang

Junwei Wu

Kristyn Gumpper

Qiwei Jiang

Duofen He

Pei-Hui Lin

Haichang Li

Fangxia Guan

Jingsong Zhou

Mark J Kohr

Chunyu Zeng

Hua Zhu

Jianjie Ma

Affiliations

Soon will be listed here.

Abstract

MG53 is a muscle-specific TRIM-family protein that presides over the cell membrane repair response. Here, we show that MG53 present in blood circulation acts as a myokine to facilitate tissue injury-repair and regeneration. Transgenic mice with sustained elevation of MG53 in the bloodstream (tPA-MG53) have a healthier and longer life-span when compared with littermate wild type mice. The tPA-MG53 mice show normal glucose handling and insulin signaling in skeletal muscle, and sustained elevation of MG53 in the bloodstream does not have a deleterious impact on db/db mice. More importantly, the tPA-MG53 mice display remarkable dermal wound healing capacity, enhanced muscle performance, and improved injury-repair and regeneration. Recombinant human MG53 protein protects against eccentric contraction-induced acute and chronic muscle injury in mice. Our findings highlight the myokine function of MG53 in tissue protection and present MG53 as an attractive biological reagent for regenerative medicine without interference with glucose handling in the body.

Citing Articles

Mitsugumin 53 Inhibits Angiogenesis Through Regulating Focal Adhesion Turnover and Tip Cell Formation.

Yuan S, Yu Q, Chen T, Li T, Li Y, Deng X J Cell Mol Med. 2025; 29(4):e70439.

PMID: 39993956 PMC: 11850094. DOI: 10.1111/jcmm.70439.

Deciphering molecular crosstalk mechanisms between skeletal muscle atrophy and KRAS-mutant pancreatic cancer: a literature review.

Guo Y, Han S, Yu W, Xu Y, Ying Y, Xu H Hepatobiliary Surg Nutr. 2025; 14(1):78-95.

PMID: 39925900 PMC: 11806137. DOI: 10.21037/hbsn-24-282.

YTHDF2 mediates the protective effects of MG53 on myocardial infarction injury via recognizing the m6A modification of MG53.

Li Z, Li K, Zhao J J Cardiothorac Surg. 2025; 20(1):121.

PMID: 39923081 PMC: 11806846. DOI: 10.1186/s13019-024-03210-y.

MG53's non-physiologic interaction with insulin receptor: lack of effect on insulin-stimulated Akt phosphorylation in muscle, heart and liver tissues.

Lee K, Nishi M, Kim J, Murayama T, Dawson Z, Wang X Front Endocrinol (Lausanne). 2024; 15:1425426.

PMID: 39355613 PMC: 11442255. DOI: 10.3389/fendo.2024.1425426.

Mitochondria-encoded peptide MOTS-c participates in plasma membrane repair by facilitating the translocation of TRIM72 to membrane.

Jia H, Zhou L, Chen Y, Zhang W, Qi W, Wang P Theranostics. 2024; 14(13):5001-5021.

PMID: 39267782 PMC: 11388074. DOI: 10.7150/thno.100321.

References

Long Y, Cheng Z, Copps K, White M . Insulin receptor substrates Irs1 and Irs2 coordinate skeletal muscle growth and metabolism via the Akt and AMPK pathways. Mol Cell Biol. 2010; 31(3):430-41. PMC: 3028618. DOI: 10.1128/MCB.00983-10. View

Yi J, Park J, Ham Y, Nguyen N, Lee N, Hong J . MG53-induced IRS-1 ubiquitination negatively regulates skeletal myogenesis and insulin signalling. Nat Commun. 2013; 4:2354. PMC: 3941707. DOI: 10.1038/ncomms3354. View

Iizuka K, Machida T, Hirafuji M . Skeletal muscle is an endocrine organ. J Pharmacol Sci. 2014; 125(2):125-31. DOI: 10.1254/jphs.14r02cp. View

Weisleder N, Takizawa N, Lin P, Wang X, Cao C, Zhang Y . Recombinant MG53 protein modulates therapeutic cell membrane repair in treatment of muscular dystrophy. Sci Transl Med. 2012; 4(139):139ra85. PMC: 3777623. DOI: 10.1126/scitranslmed.3003921. View

Yuan H, Niu Y, Liu X, Yang F, Niu W, Fu L . Proteomic analysis of skeletal muscle in insulin-resistant mice: response to 6-week aerobic exercise. PLoS One. 2013; 8(1):e53887. PMC: 3541238. DOI: 10.1371/journal.pone.0053887. View

Liu J, Zhu H, Zheng Y, Xu Z, Li L, Tan T . Cardioprotection of recombinant human MG53 protein in a porcine model of ischemia and reperfusion injury. J Mol Cell Cardiol. 2014; 80:10-19. PMC: 4512204. DOI: 10.1016/j.yjmcc.2014.12.010. View

Cai C, Masumiya H, Weisleder N, Pan Z, Nishi M, Komazaki S . MG53 regulates membrane budding and exocytosis in muscle cells. J Biol Chem. 2008; 284(5):3314-3322. PMC: 2631961. DOI: 10.1074/jbc.M808866200. View

CLARK L, CLARK R, Heber-Katz E . A new murine model for mammalian wound repair and regeneration. Clin Immunol Immunopathol. 1998; 88(1):35-45. DOI: 10.1006/clin.1998.4519. View

Ham Y, Mahoney S . Compensation of the AKT signaling by ERK signaling in transgenic mice hearts overexpressing TRIM72. Exp Cell Res. 2013; 319(10):1451-62. DOI: 10.1016/j.yexcr.2013.02.016. View

10.

Ma L, Zhang F, Qian L, Kong F, Sun J, Zhou C . Hypercholesterolemia blocked sevoflurane-induced cardioprotection against ischemia-reperfusion injury by alteration of the MG53/RISK/GSK3β signaling. Int J Cardiol. 2013; 168(4):3671-8. DOI: 10.1016/j.ijcard.2013.06.037. View

11.

Karstoft K, Pedersen B . Skeletal muscle as a gene regulatory endocrine organ. Curr Opin Clin Nutr Metab Care. 2016; 19(4):270-5. DOI: 10.1097/MCO.0000000000000283. View

12.

Ma H, Liu J, Bian Z, Cui Y, Zhou X, Zhou X . Effect of metabolic syndrome on mitsugumin 53 expression and function. PLoS One. 2015; 10(5):e0124128. PMC: 4423930. DOI: 10.1371/journal.pone.0124128. View

13.

Schnyder S, Handschin C . Skeletal muscle as an endocrine organ: PGC-1α, myokines and exercise. Bone. 2015; 80:115-125. PMC: 4657151. DOI: 10.1016/j.bone.2015.02.008. View

14.

Zhu H, Hsueh W, Whitson B . Letter by Zhu et al Regarding Article, "Glucose-Sensitive Myokine/Cardiokine MG53 Regulates Systemic Insulin Response and Metabolic Homeostasis". Circulation. 2019; 140(6):e186-e187. PMC: 9215306. DOI: 10.1161/CIRCULATIONAHA.118.039305. View

15.

Song R, Peng W, Zhang Y, Lv F, Wu H, Guo J . Central role of E3 ubiquitin ligase MG53 in insulin resistance and metabolic disorders. Nature. 2013; 494(7437):375-9. DOI: 10.1038/nature11834. View

16.

Jia Y, Chen K, Lin P, Lieber G, Nishi M, Yan R . Treatment of acute lung injury by targeting MG53-mediated cell membrane repair. Nat Commun. 2014; 5:4387. PMC: 4109002. DOI: 10.1038/ncomms5387. View

17.

Laustsen P, Michael M, Crute B, Cohen S, Ueki K, Kulkarni R . Lipoatrophic diabetes in Irs1(-/-)/Irs3(-/-) double knockout mice. Genes Dev. 2002; 16(24):3213-22. PMC: 187498. DOI: 10.1101/gad.1034802. View

18.

Liu F, Song R, Feng Y, Guo J, Chen Y, Zhang Y . Upregulation of MG53 induces diabetic cardiomyopathy through transcriptional activation of peroxisome proliferation-activated receptor α. Circulation. 2015; 131(9):795-804. DOI: 10.1161/CIRCULATIONAHA.114.012285. View

19.

Zhu H, Lin P, De G, Choi K, Takeshima H, Weisleder N . Polymerase transcriptase release factor (PTRF) anchors MG53 protein to cell injury site for initiation of membrane repair. J Biol Chem. 2011; 286(15):12820-4. PMC: 3075629. DOI: 10.1074/jbc.C111.221440. View

20.

Cooper S, Head S . Membrane Injury and Repair in the Muscular Dystrophies. Neuroscientist. 2014; 21(6):653-68. DOI: 10.1177/1073858414558336. View